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Background: Glutamate is one of the major neurotransmitters in the central nervous system. It is a potent
neurotoxin capable of neuronal destruction through numerous signal pathways when present in high
concentration. Glutamate-evoked excitotoxicity has been implicated in the etiology of many neurodegenerative
diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and ischemic stroke. Increasing evidence has
shown that reactive oxygen species (ROS) provoked by glutamate-linked oxidative stress plays a crucial role in the
pathogenesis of these disorders. We previously reported the discovery of an aryl thiophene compound, 4-chloro-N-
(naphthalen-1-ylmethyl)-5-(3-(piperazin-1-yl)phenoxy)thiophene-2-sulfonamide (B355252) from a proprietary library
of small molecules. We showed that this compound was capable of potentiating nerve growth factor (NGF)-primed
neurite outgrowth in neuronal cell models in a low NGF environment. In the present study we investigated the
neuroprotective effects and signaling pathways of B355252 on glutamate-evoked excitotoxicity in HT-22, a murine
hippocampal neuronal cell line.
Results: Glutamate significantly decreased HT-22 neuronal cell viability in a concentration-dependent manner as
measured by the MTT assay. Co-treatment with 2, 4, and 8 μM B355252 protected against cell death caused by
glutamate-induced toxicity by 9.1% (p<0.01), 26.0% (p<0.001), and 61.9% (p<0.001) respectively, compared to
glutamate-treated control group. B355252 at a concentration of 8 μM fully rescued HT-22 from the neurototoxic effects
of glutamate, and by itself increased cell viability by 16% (p<0.001) above untreated control. Glutamate enhanced
reduction in glutathione (GSH) synthesis was reversed by 15% (p<0.01) in the presence of B355252. B355252 reduced
the expression of apoptosis inducing factor (AIF) by 27%, while the proapoptotic Bcl-2 associated X protein (Bax) was
strongly attenuated 3-fold. Glutamate-evoked increase in intracellular calcium (Ca2+) load and subsequent ROS
production was inhibited by 71% (p<0.001) and 40% (p<0.001) respectively, to comparable level as untreated control in
the presence of B355252. Glutamate significantly upregulated the phosphorylation of extracellular signal regulated
kinase Erk1/2 (pERK1/2), while decreasing Erk3. In contrast, B355252 potently attenuated the glutamate-dependent
activation of Erk1/2 and robustly increased the level of ERK3 in HT-22.
(Continued on next page)* Correspondence: gibeanu@nccu.edu
1BRITE, North Carolina Central University, 1801 Fayetteville Street, Durham,
NC 27707, USA
3Department of Pharmaceutical Sciences, North Carolina Central University,
1801 Fayetteville Street, Durham, NC 27707, USA
Full list of author information is available at the end of the article
© 2013 Gliyazova et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Gliyazova et al. BMC Neuroscience 2013, 14:93 Page 2 of 13
http://www.biomedcentral.com/1471-2202/14/93(Continued from previous page)
Conclusions: A novel phenoxy thiophene small molecule, B355252, suppresses glutamate-evoked oxidative stress in
HT-22 neurons by blocking Ca2+ and ROS production, and altering the expression or phosphorylation states of Erk
kinases. This molecule previously reported to enhance neurite outgrowth in the presence of sub-physiological
concentrations of NGF appears to be a promising drug candidate for development as a potential therapeutic and
neuroprotective agent for various neurodegenerative disorders.
Keywords: Glutamate, Neuroprotection, Excitotoxicity, Small molecule, Alzheimer’s disease, Oxidative stress, ERK3,
Neurodegenerative disease, Phenoxy thiophene, HT-22Background
Several neuropathological processes are associated with
glutamate excitotoxicity and oxidative stress that lead to
neuronal damage and death. Despite concerted effort in
recent years to develop new and effective drugs to com-
bat diseases triggered by glutamate excitotoxic cascade,
there have been few therapeutic advances in the treat-
ment of these devastating conditions. Glutamate is the
most abundant neurotransmitter in the brain and plays a
crucial role in neuronal tissue damage during cerebral
ischemic hypoxia caused by toxic levels of the neuro-
transmitter in the central nervous system [1]. The
resulting decrease in ATP levels under toxic glutamate
conditions leads to failure of energy-dependent sodium
pumps, anion channels, membrane depolarization, and
glutamate secretion.
The tonic basal concentration of extracellular glutam-
ate in the brain under normal physiologic condition has
been estimated in the range 1–30 μM [2]. This concen-
tration determines its role in metabolic processes.
Contradictory reports exist in the literature on the brain
levels of glutamate in neuropsychiatric disorders. Previ-
ous reports point to decreased levels of glutamate in
Alzheimer’s disease [3,4], while increased plasma levels
of glutamate have been reported in epilepsy, Alzheimer’s
disease, and amyotrophic lateral sclerosis [5-7]. In the
case of Alzheimer’s disease, recent research suggests a
mechanism whereby amyloid beta decreases the uptake
of glutamate at the synapse resulting in excess glutamate
in the extracellular space outside the synaptic terminal.
The excess glutamate leads to activation of glutamate re-
ceptors and is thought to play a role in the pathophysi-
ology of the diseases.
Glutamate exerts its effects via three membrane proteins
composed of two major classes of receptors and a cystine/
glutamate antiporter protein. Under normal physiological
conditions, glutamate released in the synaptic cleft binds the
two major types of post-synaptic glutamate receptors, the
metabotropic glutamate receptors (mGluR) and ionotropic
glutamate receptors (iGluR). The iGluR consists of three
members: N-methyl-D-Aspartic acid (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and
kainic acid (KA) receptors, while the mGluR has eightmembers (mGluR1-8). The mGluRs in concert with the
iGluRs facilitate synaptic plasticity, learning, memory and
other cognitive functions [8,9].
Glutamate-induced cell death is mediated in part by ac-
cumulation and overstimulation of the postsynaptic glu-
tamate receptor system [10]. Chronic exposure of neurons
to glutamate results in persistent activation of glutamate
receptors, which destabilizes the tightly controlled mecha-
nisms that regulate Ca2+ homeostasis in neurons. Perturb-
ation of intracellular Ca2+ balance drives the accumulation
of Ca2+ ions in the mitochondria and leads to bioenergetic
failure as a result mitochondrial membrane depolarization
linked to opening of the mitochondrial permeability transi-
tion pore. The subsequent activation of Ca2+-dependent
enzymes negatively impacts a large number of Ca2+ medi-
ated functions and lead to a cascade of events that culmin-
ate in neuronal injury and cell death [11,12]. There is
abundant evidence that prolonged exposure to high con-
centrations of extracellular glutamate promotes oxidative
toxicity in cells that do not express functional iGluR such
as HT-22 neurons, primarily by activation of mechanisms
that negatively impact the function of the cystine/glutamate
antiporter [13]. The resulting decrease in cystine uptake
across the cell membrane lowers intracellular levels of the
free radical scavenger glutathione (GSH). Depletion of
GSH leads to oxidative stress that is accompanied by
downregulation of the cystine-dependent antioxidant sys-
tem, formation of ROS, and alteration in Ca2+ homeostatic
mechanisms resulting in cell death [14].
Oxidative stress has emerged as a major mechanism that
underlies the etiology of a variety of neuropathological dis-
orders, including ischemic stroke, traumatic brain injury
(TBI), depression, Alzheimer’s disease, Parkinson’s disease
[15-20]. Most neurodegenerative diseases are character-
ized by progressive neuronal atrophy and cell death in the
central and peripheral nervous system. In the case of
Alzheimer’s disease, the leading cause of dementia in the
elderly population, there is a significant loss of cholinergic
neurons in brain regions associated with learning and
memory including the hippocampus, amygdala, and cor-
tex, resulting in decline in cognitive, behavioral, and func-
tional abilities. Past studies suggest that oxidative damage
to proteins, lipids, and DNA may contribute to neuronal
Figure 1 Glutamate-dependent toxicity in HT-22 cells is
concentration dependent. HT-22 was treated with the indicated
concentrations of glutamate and cell viability assessed with MTT
assay. Cells exposed to glutamate concentrations greater than
2.5 mM showed significant decrease in cellular viability. Glutamate
exhibited a LD50 of 3.0 mM in HT-22 (inset). Values represent the
means ± SD as a percent (%) of control (*p<0.05, ***p<0.001).
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gered by amyloid beta (1–42) peptide induce an increase
in nitric oxide synthase, formation of ROS, and alteration
of mitochondrial dynamics [23-25]. More recently, the
role of amyloid beta peptide in elevating intracellular Ca2+
levels through mechanisms involving NMDA and AMPA
receptors resulting in disregulation of synaptic transmis-
sion and cell death was demonstrated in the early phase of
Alzheimer’s disease [26,27]. Taken together, these studies
suggest a potential role for oxidative stress and regulation
of calcium homeostasis as a possible factor contributing to
the death of cholinergic neurons in Alzheimer’s disease.
Previously, we reported the identification of an aryl-
thiophene compound (B355252) that potentiates NGF-
primed neurite outgrowth (NOG) in NS-1 cell, a derivative
of the pheochromocytoma PC12 cell line [28]. This com-
pound is devoid of NOG properties alone but promotes
the differentiation and elongation of axonal-like pro-
cesses in vitro in the presence of sub-physiological con-
centrations of NGF as exists in brain regions affected
by Alzheimer’s disease. In the present study, we investi-
gated the neuroprotective effect of B355252 in an oxida-
tive glutamate excitotoxicity model in HT-22 neuronal
cell line, and sought to elucidate the underlying molecular
pathway.
Results
Prolonged exposure of HT-22 to glutamate triggers dose-
dependent cytotoxic effect
We first determined the toxic effect of glutamate in HT-
22 cultures in concentration-dependent assays. Cell via-
bility was measured with MTT. Glutamate treatment of
HT-22 led to progressive significant reduction in cell via-
bility with increasing glutamate concentration (Figure 1).
At 2.5 mM glutamate dose the number of viable cells de-
creased by roughly 25% (p<0.05) compared to untreated
cells. When glutamate concentration was doubled to
5 mM, cell viability decreased by 75% (p<0.001) compared
to the untreated cultures. At 10 mM glutamate, the viabil-
ity of HT-22 decreased by nearly 83% (p<0.001) of un-
treated cells with no additional toxicity observed when
glutamate was increased to 15 mM and 20 mM. The me-
dian lethal dose (LD50) of glutamate for HT-22 in this ex-
periment is 3.0 mM (Figure 1 inset).
Exposure of cells to B355252 prevents glutamate-induced
excitotoxicity
To assess the neuroprotective effect of B355252 under
conditions of glutamate toxicity, HT-22 was challenged
with 5 mM glutamate with and without pretreatment of
B355252. The protective effect was analyzed with MTT
assay 10 h after glutamate treatment. Cell viability in the
glutamate treated population significantly declined by
nearly 60% (p<0.001) compared to the untreated cells(Figure 2A). Pretreatment of cells with B355252 before
glutamate exposure protected HT-22 from cell death by
counteracting the toxic effect of glutamate. In the pres-
ence of 2 μM, 4 μM, and 8 μM compound, statistically
significant increases in cell survival of 9.1% (p<0.01),
26.0% (p<0.001), and 61.9% (p<0.001) were observed re-
spectively, compared to cells treated with glutamate
only. Notably, at a concentration of 8 μM, B355252 fully
protected HT-22 against the harmful effects of glutamate
with cell viability attaining equivalent levels as that of
the untreated control group. Interestingly, treatment
with B355252 alone promoted cell proliferation by more
than 16% (p<0.01) over control group.
We next confirmed these results in a qualitative visual
fluorescent cell viability staining assay employing two
fluorescent dyes, acridine orange (AO) and ethidium
bromide (EB). AO/EB stains allow for rapid discrimination
of viable and dead cells when visualized by fluorescence
microscopy. AO is a cell-permeable dye that traverses the
cell membrane and stains the nucleus of viable cells bright
green, while EB stains dead cells red-to-orange, and is ex-
cluded by viable cells. Glutamate treated HT-22 cells
evoked a significant decrease in cell viability as demon-
strated by a sharp increase in the ratio of red to green
cells observed in a phase contrast microscopy image
(Figure 2B), confirming the data set obtained with the
MTT assay. Conversely, pretreatment with B355252
protected HT-22 against glutamate injury as observed
by the increase in the number of cells emitting green
fluorescence (AO) relative to the red fluorescence of EB
(Figure 2C). The AO fluorescence of B355252 protected
cells closely matched the fluorescence of the control
B C D
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Figure 2 Neuroprotective effects of B355252 against glutamate-induced toxicity. HT-22 cells were treated with or without glutamate and
the indicated concentrations of B355252 and analyzed with the MTT assay (A), or a fluorescent viability assay (B, C, D). (A). B355252 conferred
significant dose-dependent protection against glutamate toxicity compared to the untreated control. B355252 also displayed cell proliferative
effect in the absence of glutamate (*p<0.05, ***p<0.001 compared to glutamate-treated cells; ###p<0.001, +++p<0.001 compared to control).
Representative morphology of glutamate treated cells (B), cells protected from glutamate toxicity by B355252 (C), and untreated control cells (D).
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has the functional capacity to rescue cells from glutamate
evoked neurotoxicity, and possesses activity that promotes
cellular proliferation.
B355252 modulates GSH expression and depletes
glutamate enhanced expression of AIF and Bax
To ascertain how B355352 confers protection against
glutamate-induced cell death we measured the level of
reduced GSH, and two apoptosis associated proteins Bax
and AIF in experimental and control cells, since glutam-
ate has been documented to upregulate the levels of
these proteins in neuronal cells. Glutamate treated cells
showed a 40% (p<0.001) reduction of GSH in HT-22
compared to untreated cells (Figure 3A). Pretreatment
of B355252 slightly reversed the effect of glutamate
dependent-decrease of GSH in the cells by 15% (p<0.01)
compared to glutamate treatment but was unable to re-
store GSH to comparable level as in untreated cells. In
the case of the proapoptotic proteins AIF and Bax, theimmunoblot analysis of cellular lysates revealed that glu-
tamate significantly increased AIF in HT-22 cells by 40%
compared to control cells (Figure 3B). This effect was re-
duced by 27% when cells were pretreated with B355252.
Also, the expression of Bax by glutamate was significantly
increased by more than 3-fold compared with expression
in untreated cells. Pretreatment of B355252 before glu-
tamate significantly blocked the expression of Bax protein,
essentially reducing it to a level that is comparable to that
of untreated cells. These results suggest that B355252 pro-
tects against glutamate-induced oxytosis and apoptotic
cell death in HT-22 through a reversal of GSH depletion
and robust repression of proapoptotic Bax expression.
Exposure of cells to B355252 protects against glutamate-
induced calcium overload
In order to evaluate the effect of B355252 against
excitotoxicity promoted by Ca2+ accumulation, HT-22
cells were treated with glutamate in the presence or ab-
sence of the test compound. The results indicate that
AB
Figure 3 B355252 partially restores glutamate-induced depletion of GSH and attenuates the increases in AIF and Bax expression in
HT-22 cells. HT-22 cells were pretreated with B355252 for 2 h prior to glutamate addition for 10 h as described in the Methods. The level of GSH
was measured in the cellular lysates with monochlorobimane (MCB) and glutathione-S-transferase (GST). AIF and Bax protein levels were
determined by immunoblot with anti AIF and anti Bax antibodies. GAPDH was used to normalize for variations in protein loading. (A), Expression
of GHS (B), Immunoblots of AIF and Bax. The bars depict densitometric analyses of the relative values of AIF (top bar graph) and Bax (lower bar
graph) present in glutamate treated, glutamate and B355252 treated, and control cells (***p<0.001 compared to glutamate-treated cells).
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Ca2+ as measured by the fluorescence of Ca2+-bound
Fura 2-AM by 93% (p<0.001) compared to control cells
(Figure 4). In the presence of B355252, the intracellular
Ca2+ load declined significantly by nearly 71% (p<0.001)
compared to cells treated solely with glutamate. This re-
sult implies that B355252 potentially prevents cell death
and improves cell survival by modulating intracellular
Ca2+ overload in HT-22 cells under glutamate insult.
Glutamate-dependent accumulation of ROS is muted by
B355252
Since oxidative stress mediates glutamate induced cell
death in HT-22 cells via ROS accumulation we exam-
ined the role of B355252 in oxidative stress promoted byglutamate toxicity. Intracellular ROS activity was mea-
sured after exposure of HT-22 to glutamate. As shown in
Figure 5, the incubation of cells in glutamate stimulated
an increase in intracellular ROS by nearly 40% (p<0.001)
of control value. When the cells were pretreated with
B355252 the level of ROS was significantly reduced by
40% (p<0.001) similar to the level observed in untreated
cells, which suggest that B355252 protects cells against
glutamate injury through the abatement of ROS produc-
tion. Cells treated with B355252 alone exhibited no signifi-
cant alterations in the burden of ROS.
Erk phosphorylation is attenuated by B355252
Persistent activation of Erk1/2 by glutamate has been
found to trigger cell death in primary cultures of rat
Figure 4 B355252 inhibits glutamate-induced accumulation of
intracellular Ca2+. HT-22 was exposed to glutamate alone and in
the presence of B355252. Changes in intracellular Ca2+ load was
measured with the calcium binding dye Fura-2. Accumulation in Ca2+
by glutamate treatment was significantly attenuated by 8 μM of
B355252. B355252 alone did not alter Ca2+ homeostasis in the cell.
(***p<0.001 compared to glutamate-treated cells; ###p<0.001
compared to control).
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whether prevention of glutamate toxicity by B355252 in-
volves significant downregulation of Erk1/2 activity we
measured the activation state of Erk1/2 by probing im-
munoblots of cytosolic and nuclear fractions of HT-22
with total and phospho-Erk1/2 (pERK) antibodies. Im-
munoblotting with anti-Erk1/2 in glutamate treated cells
demonstrated that prolonged exposure of HT-22 to toxic
levels of glutamate increased the total Erk1/2 proteins
present in the cytosolic fraction by 12% of controlFigure 5 Glutamate-evoked production of ROS is blocked by
B355252 in HT-22 cells. HT-22 was exposed to B355252 for 2 h,
and then treated with glutamate for 10 h. ROS level was measured
with CellRox Deep Red. Glutamate-dependent elevation of ROS was
significantly attenuated by pretreatment of cells with B355252
(8 μM). B355252 alone did not significantly affect ROS level in the
cell (***p<0.001 compared to glutamate-treatment; ###p<0.001
compared to control).(Figure 6A). However, the active form of Erk1/2 (pERK1/2)
was drastically increased by 86% (p<0.001) in glutamate
treated cells when compared to untreated cells. Similarly,
there was no significant difference in the level of total Erk
in the nuclear fraction of glutamate treated cells but a
significant amount of pERK was present in the nucleus of
glutamate treated cells (Figure 6B). When cells were
pretreated with B355252, the immunoblots revealed no al-
terations in the expression levels of total Erk1/2 proteins in
either the cytosolic or nuclear fractions compared to con-
trols (Figure 6A and 6B). However, the glutamate evoked
activation of Erk as observed with anti-pERK antibody was
significantly reduced by 89.8% (p<0.001) in the cytoplasmic
fraction upon treatment with B355252 and was not
detected in the nucleus in comparison to glutamate ex-
posed cells (Figure 6B). Exposure of cells solely to B355252
neither resulted in increased expression or activation of
Erk1/2. These results confirm that glutamate alters the ac-
tivation state of Erk1/2 in HT-22.
Inhibition of Erk3 activation by glutamate is derepressed
by B355252
To further determine the influence of B355252 on other
members of the Erk family that are highly expressed in
neuronal cells, we analyzed the effect of B355252 on
Erk3 in HT-22 cells under glutamate stress with immu-
noblot using anti ERK3. We tested the possibility that
glutamate toxicity interferes with the expression of Erk3
and that B355252 could reverse the effect. Indeed when
HT-22 cells were treated with glutamate the level of
ERK3 was significantly decreased by 64% (p<0.001) com-
pared to control cells (Figure 7). Pretreatment with
B355252 altered the glutamate-dependent inhibition by
restoring the expression of Erk3 to 96% (p<0.001) of the
level observed in untreated sample. Sole treatment of
HT-22 with B355252 did not significantly alter the cellu-
lar content of ERK3. This observation indicates that
B355252 could indeed restore the level of Erk3 in neur-
onal cells under glutamate stress by directly blocking the
effect of glutamate or upregulating the level of Erk3 in
the cell.
Discussion
Neurodegenerative diseases share a common mechanism
of pathophysiology such as oxidative stress, mitochon-
drial aberrations, and inflammation, which lead to the
degeneration and death of neurons. Developing thera-
peutics modulators of these universal mechanisms could
have a significant impact in the management of these
devastating diseases through delay of disease onset or
disease progression. The interaction of glutamate with
specific membrane receptors is responsible for many
neurological actions mediated by neuronal cells in the
CNS, including synaptic plasticity, sensation, and
BA
Figure 6 Glutamate-dependent activation of Erk1/2 is blocked by B355252 in HT-22 cells. Cultured cells were treated with glutamate 10 h
following a 2 h pretreatment with B355252. Cellular fractions (cytosolic and nuclear) were prepared and subjected to immunoblot analysis with
total Erk1/2 or pERK1/2 specific antibodies. Membranes were reprobed with GAPDH and H3 histone specific antibodies as controls for protein
loading. (A). Cytoplasmic fraction probed with total Erk1/2 (top), pERK1/2 (middle), and GAPDH (bottom) specific antibodies. Erk activation by
glutamate was significantly attenuated by pretreatment of cells with B355252 (8 μM). B355252 alone had no effect on phospho-Erk1/2. The bar
graph in figure A shows the relative level of active Erk in the samples. ***p<0.001 compared to glutamate-treated cells. (B) Nuclear fractions of
samples probed with total Erk1/2 (top), pERK1/2 (middle), and H3 histone (bottom) specific antibodies. +/− indicates presence or absence
of compounds.
Figure 7 B355252 restores glutamate-evoked reduction of ERK3 expression in HT-22 cells. Cultured cells were treated with glutamate,
with and without B355252. Cell lysates were prepared, subjected to SDS-PAGE, and immunoblotted with ERK3 specific antibody. Membrane was
reprobed with anti-GAPDH and used to normalize gel loading. The bar graph shows the relative levels of Erk3 in the samples. Glutamate-
dependent attenuation of ERK3 was reversed by treatment with B355252 (8 μM). B355252 exclusively had no significant effect on the basal level
of ERK3 (***p<0.001 compared to glutamate-treated cells).
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http://www.biomedcentral.com/1471-2202/14/93movement [32-34]. However, excessive glutamate can
lead to neuronal cell death in a variety of pathological
conditions which is thought to play a crucial role in the
pathogenesis of many neuropsychiatric and neurodegen-
erative disorders [35]. In a previous study, we described
the synthesis and identification of a novel phenoxy thio-
phene sulphonamide small molecule (B355252) enhan-
cer of neurotrophin-dependent signaling, which
promotes neurite outgrowth, extension, and cell survival
[28], functions under assault in many neurological disor-
ders. In the present study we demonstrate the ability
B355252 to rescue HT-22 neuronal cells from glutamate-
induced neurotoxic injury and sort to define the cellular
events that underlie the rescue. Our results strongly sug-
gest that B355252 prevents glutamate neurotoxicity
through multiple effects targeted at mitochondria-
dependent events including inhibition of Ca2+ overload,
depletion of ROS, restoration of glutathione, and expres-
sion of the apoptotic proteins AIF and Bax. In addition
B355252 exerted its effect by modulating the activity of
typical and atypical the Erk family members.
Glutamate induces apoptosis at high concentrations in
neurons, and HT-22 cells provide a model system to
study glutamate-evoked death signaling pathways that
enhance ROS formation and oxidative stress independ-
ent of NMDA-receptor.
These cells lack ionotropic glutamate receptors, but
are still sensitive to high concentration of extracellular
glutamate, which depletes glutathione and causes oxida-
tive toxicity in an Erk-dependent manner. There is wide
variation in the literature on the concentration of glu-
tamate that induces oxidative toxicity in HT-22 cells. In
these studies, the dose of glutamate used to induce cell
death following 24 h treatment varied between 1 mM
and 10 mM, while the rate of induction of cell death var-
ied between 10% and 90% [30,31,36]. Based on the varia-
tions in glutamate concentration in these studies we
determined the effective concentration of glutamate for
our experiment in a dose response assay. Prolonged
treatment with glutamate for 10 h triggered significant
concentration-dependent cell death in HT-22 as mea-
sured by decrease in cell viability and EB fluorescence
staining (Figure 1; Figure 2B). The B355252 dose-
dependently protected the cells and consequently
prevented the harmful effect of glutamate on HT-22
cells by restoring the cell health of HT-22 to comparable
level as that of naïve cells at a concentration of 8 μM
(Figure 2A). In addition to its neuroprotective attributes
B355252 also exhibited intrinsic proliferative activity by
stimulating cell growth in HT-22 neurons. These results
indicate that cell death promoted by glutamate toxicity
could be ameliorated by B355252 and support a
neuroprotective role and therapeutic potential for the
compound.Substantial controversy exists in the literature with re-
gard to how glutamate mediates its toxic effect in HT-22.
Glutamate evoked oxidative death result in a time and
concentration-dependent manner from mechanisms that
involve both necrotic and apoptotic processes [30,37,38].
However, apoptosis appears to be more intimately in-
volved in the process at late time points. Previous studies
suggest that glutamate induces a particular type of a
caspase-independent cell death called oxytosis, which in-
volves the translocation of AIF from the mitochondria to
the nucleus [39,40]. Immunoblot studies with anti AIF
antibody show that AIF was marginally increased by glu-
tamate treatment in the HT-22 cells (Figure 3B). This ob-
servation implies that AIF plays a role in glutamate-
induced death but most likely does not represent a major
cell death pathway in our current study, which is in
agreement with previously published results [41]. The
glutamate induced expression of AIF was inhibited to
background level in the presence of B355252 (Figure 3B).
It is unclear whether B355252 acts by direct perturbation
of AIF translocation, at upstream regulators of AIF such
as PARP, or whether the compound destabilizes released
AIF and promotes its clearance in the cytosol.
Recent evidence has shown that exposure to glutamate
regulates the expression of the proapoptotic Bax protein
in HT-22 [41]. Bax specific inhibitors, antioxidants, and
anti-inflammatory agents were capable of protecting
against glutamate-induced cell death in neurons by
blocking the expression of Bax [42,43]. In our study, im-
munoblots probed with Bax specific antibody show that
glutamate stimulated increased expression of Bax in
HT-22 (Figure 3B), which supports the conclusion that
prolonged treatment of HT-22 cells with glutamate leads
to apoptosis. This observation is in agreement with
widely published data on the mechanism of cell death
caused by glutamate exposure. Our results show that the
glutamate-evoked Bax expression was sharply blunted by
B355252. Based on the expression level in the presence
of B355252, the substantial reduction in the amount of
Bax to a large extent suggests that B355252 is a highly
effective inhibitor of a major glutamate cell death path-
way caused by the accumulation of proapoptotic Bax
protein.
A major event during programmed cell death is an in-
crease in cytosolic Ca2+ [44]. Under normal physiological
conditions glutamate-induced cell signaling intermedi-
ates such as Ca2+ influence a wide variety of cellular
components and play a fundamental role in neuronal
survival, differentiation, and development of synaptic cir-
cuits [11]. However, it has been shown that Ca2+ is a key
mediator of numerous cell death pathways and that a
complex relationship exists between mitochondrial func-
tion, ROS, Ca2+, and cell death [45]. Elevation of intra-
cellular Ca2+ is a hallmark of excitotoxicity triggered by
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cells. Ca2+ overload excessively activate Ca2+ signal
transducers, which increase the vulnerability of neurons
to cell damage or death. Previous studies have shown
that inhibition of Ca2+ influx relieves glutamate neuro-
toxicity in HT-22 cells [46]. In the present study, intra-
cellular Ca2+ in HT-22 cells was significantly elevated by
glutamate treatment in agreement with past research
findings. Subsequent treatment with B355252 caused a
marked decrease in glutamate-induced Ca2+ overload
(Figure 4). Since disregulation of the Ca2+ homeostasis
has been identified as a key factor in glutamate toxicity
[10,12], the observed effect of B355252 suggest that the
compound interferes with glutamate activity or mechan-
istically restores Ca2+ balance in cells under glutamate
assault leading to cell survival.
The production of ROS induced by oxidative stress
has been noted in various studies of glutamate toxicity,
suggesting that accumulation of ROS play a crucial role
in the induction of cell death by glutamate. Previously
studies show that protracted exposure of HT-22 to
extracellular glutamate prevents cystine uptake into the
cells via the cystine/glutamate antiporter, resulting in de-
pletion of intracellular GSH. Both reduced GSH levels
and increased ROS formation are established mecha-
nisms that contribute to neuronal death in models of
chronic and acute neurodegeneration. Reduced supply of
glutathione, leads to influx of extracellular Ca2+ and ac-
cumulation of excessive amounts of ROS, which in turn
leads to oxidative stress. Furthermore, elevated ROS
level results in damage to macromolecules neurons. Ex-
cessive ROS must be promptly eliminated from the cell
by a variety of antioxidant defense mechanisms that
scavenge ROS if cells are to be protected from oxidative
damage. In this study we observed that treatment of
HT-22 with glutamate resulted in oxidative stress char-
acterized by depletion of GSH, elevated production of
ROS, and changes in cell morphology as reported in the
literature. Pre-exposure of HT-22 cells to B355252
blocked glutamate-induced death through mechanisms
that involve both increase in cellular GSH (Figure 3A)
and reduction of ROS (Figure 5). Antioxidant scavengers
such as N-acetylcysteine (NAC) and trolox prevent
glutamate-induced cell death in HT-22 by sustaining cel-
lular glutathione and reduction of ROS [30,47]. Thus,
the present finding support the conclusion that B355252
acts as oxidant scavenger and the neuroprotection con-
ferred on HT-22 may be dependent in part on its anti-
oxidant attributes.
The superfamily of mitogen-activated protein kinases
(MAPKs) which include extracellular signal-regulated ki-
nases (Erks), c-Jun NH2-terminal kinase (JNK), and p38
MAP kinase modulate in a variety of cellular function in
many cell types [48]. The Erk subfamily comprises 5different isoforms, Erk1 to Erk5. Although Erks are trad-
itionally viewed as a survival factor recent reports have
demonstrated a death-promoting role for Erks in neur-
onal cells [30,31,49]. Erk1/2 has been implicated in
glutamate-induced neuronal oxidative toxicity based
upon the observation that U0126, a specific inhibitor of
the Erk-activating kinase, MEK-1/2, protects both HT-22
cells and immature primary cortical neuron cultures
from glutamate toxicity [31]. Administration of U0126
following focal ischemia in rodents led to a reduction in
brain injury suggesting that Erk1/2 may also promote
neuronal cell death as a consequence of acute injury
in vivo [50]. Our results confirmed that U0126 could
prevent glutamate-induced cell death in HT-22 by re-
duction of Erk phosphorylation (data not shown). Simi-
larly, B355252 protected against glutamate toxicity via
inhibition of Erk activation (Figure 6), but not JNK or
P38 activation (data not shown), clearly demonstrating
the involvement of Erk1/2 activation in the protection
conferred by B355252. Furthermore, the activation of
Erk1/2 in the glutamate excitotoxic model has been tightly
linked to ROS production partly through Ca2+-sensitive
signals [51]. These Ca2+-permeable pathways upregulates
Ca2+ influx, which in turn activates several Ca2+-dependent
kinases to increase Erk phosphorylation. However,
some research reports have indicated that activation of
Erk in HT-22 is independent of ROS accumulation.
This conclusion is supported by the observation that
U0126 was unable to block the generation of intracellu-
lar ROS during activation of Erk 1/2 in a glutamate
excitotoxic model [31]. In the current study the pro-
duction of intracellular ROS by glutamate and activa-
tion of Erk1/2 were significantly reduced in cells that
are protected by B355252. These data support the view
that B355252 unlike U0126 exerts it effects through mul-
tiple functional pathways, which influence glutamate-
evoked activation of Erk1/2 and accumulation of ROS in
promoting cell survival during glutamate toxicity. The
mechanisms by which B355252 exerts these actions re-
main to be determined.
Erk3 is an atypical member of the mitogen-activated
protein kinase (MAPK) family of serine/threonine ki-
nases. Little is known about the biological function of
Erk3 and even less about its regulation, substrate specifi-
city, and cellular targets. Erk3 is abundantly expressed in
neurons were it is found in both the cytoplasm and nu-
cleus. Although its physiological functions remain to be
established, signaling by Erk3 kinase has been theorized
to play a role in neuronal morphogenesis and survival
and in the regulation of cell growth and differentiation
[52,53]. Recent work has shown that Erk3 interacts with
and activates the MAP kinase-activated protein kinase
MK5 and has been reported to inhibit S-phase transition
in fibroblasts upon serum activation, which suggest that
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cellular conditions. However, it is unclear whether Erk3
regulates cell proliferation under physiological condi-
tions. Research has shown that Erk3 kinase increases
during differentiation of PC12 into neuronal lineage and
that Erk3 mRNA is tightly regulated during mouse de-
velopment, suggesting a role for Erk3 in embryogenesis
[54,55]. Recently, Erk3 was found to form a ternary
complex with MK5 and septin7 to promote dendrite de-
velopment and spine formation in MK5 mouse knockout
suggesting a role in the regulation of neuronal morpho-
genesis and survival [56]. In our study, glutamate treat-
ment substantially blunted the expression of Erk3 in
contrast to increased phosphorylation of Erk1/2. Treat-
ment of cells with B355252 led to increase in the magni-
tude of Erk3, restoring the expression of the kinase
(Figure 7). B355252 alone had no effect on the expres-
sion of pERK3, which suggests that pERK3 does not play
a role in B355252-dependent cell proliferative activity.
Taken together, the results of Erk regulation signify that
B355252 protects HT-22 from glutamate-evoked neuro-
toxicity by opposing the deleterious effects of glutamate
through coordinated restoration of typical and atypical
Erk kinases.
Conclusion
In this study we have shown that a novel phenoxy thio-
phene compound, B355252 protects against oxidative
stress in a glutamate-evoked oxidative neurotoxicity model.
Glutamate at toxic concentrations perturbs Ca2+ homeo-
static mechanisms and leads to ROS generation. Also, ex-
cess glutamate depletes glutathione and upregulates the
expression of AIF and Bax. In addition, glutamate targets
the Erks, triggering opposing effects in the activation states
of typical and atypical Erk kinases in HT-22 cells. The mo-
lecular mechanisms responsible for the protection of
B355252 against glutamate injury in this neuronal cell line
involves the restoration of Ca2+ homeostasis, suppression
of ROS production, inhibition of AIF and Bax expression,
and re-establishment of the dynamic interplay between the
activation states of Erk1/2 and Erk3 kinases. In an earlier
study we showed that B355252 possesses neuritogenic and
NGF-dependent neurite outgrowth properties and our
current finding demonstrate that this compound possesses
robust antioxidant properties. Overall, the cumulative data
on B355252 from our laboratory suggest that it is a prom-
ising small molecule with the potential for development as




Phospho-Erk1/2 (pERK1/2) rabbit monoclonal antibody,
ERK3, and histone H3 rabbit antibody were purchasedfrom Cell Signaling Technology (Danvers, MA) and Epi-
tomics, Inc (Burlingame, CA). Goat anti-GAPDH [HRP]
polyclonal antibody was from GenScript (Piscataway, NJ).
L-glutamic acid monosodium hydrochloride was obtained
from Sigma (St. Louis, MO) and B355252 was synthesized
according to Williams et al. [28].Cell culture and treatment
HT-22 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; ATCC, Manassas, VA) supplemented
with 10% fetal bovine serum (FBS; Gibco BRL, Grand Island,
NY), penicillin (100 U/mL), and streptomycin (100 μg/mL),
at 37°C in a humidified atmosphere of 5% CO2. B355252
synthesized as previously described was prepared in DMSO
at a stock solution concentration of 10 mM. The final con-
centration of DMSO was 0.1% in the cell cultures used in
the present study. For experiments, actively growing cells
were seeded at 2×104 cells/well of 96-well culture plate or
5×105 cells/well of 6-well cell culture plate and incubated
for overnight prior to pretreatment for 1 h with compound
and glutamate treatment for a period of 10 h.Assessment of cell viability
Cell viability was evaluated biochemically with the MTT (3-
[4,5-dimethylthiazole-2-yl]2,5-diphenyl tetrazolium brom-
ide) and visually with ethidium bromide (EB)/acridine
orange (AO) fluorescent assay. The MTT assay is based on
the capacity of cellular mitochondrial NADPH dehydroge-
nases to reduce the yellow water-soluble tetrazolium sub-
strate into a dark blue/purple water-insoluble formazan
product in viable cells. Cells seeded overnight in 96-wells
plates were treated with glutamate with or without the
B355252. At the end of the exposure period, MTT was
added to a final concentration of 1 mg/ml to each well and
the plates returned to the incubator for 3 h. The medium
was carefully removed, the cells rinsed once with PBS and
150 μL DMSO was added to lyse the cells. Components of
the wells were mixed thoroughly with repeated pipeting
until the formazan crystals were completely dissolved.
Changes in the absorbance of formazan dye in live cells
were measured using a PheraStar multipurpose plate reader
(BMG Labtech, Durham, NC) at 490 nm. The extent of
MTT conversion in treated cells was expressed as a per-
centage of the viability of the control cells.
For the fluorescent visualization assay, EB/AO solu-
tion was prepared as a 100X stock solution containing
1 mg/mLEB and 0.3 mg/mL AO in 2% ethanol and
stored at −20°C in 1 mL aliquots. HT-22 cells were cul-
tured in 6-well plates and treated as described above.
At the end of the incubation period, the samples were
rinsed with PBS, stained with a cocktail of AO/EB di-
luted to 1X in phenol free DMEM, and immediately
document by fluorescence microscopy utilizing green
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(510/595 nm; ex/em).
Measurement of reduced glutathione
GSH content was assayed with the monochlorobimane
(MCB) glutathione detection kit (Biotium, Hayward,
CA). MCB is non-fluorescent dye in with high affinity
for GSH. MCB becomes highly fluorescent (ex/em=390/
490) upon reacting with GSH in the presence of
glutathione-S-transferase (GST). To assay for GSH con-
tent, cells cultures treated with B355252 and/or glutam-
ate as previously described were detached and
centrifuged in a microcentrifuge tube at 700 × g for
5 min. The cells were washed once with ice cold PBS at
4°C and assayed according to the protocol provided by
the kit manufacturer. Reduced glutathione was used as a
positive control.
Measurement of intracellular Ca2+ increase
HT-22 cells were cultured and treated as described for
the viability assessment assay. After incubation with
B35525, control and drug-treated cells were washed with
PBS and loaded with 5 μM Fura-2AM for 45 min at 37°C.
Loaded cells were washed twice with DPBS and the
amount of intracellular Ca2+ was determined in a
SpectraMax Plus384 (Molecular Devices) by successive
excitation of the Fura-2 dye with a xenon light source at
340 and 380 nm. The emitted fluorescence was passed
through a 510-nm filter, recorded and analyzed with
SoftMax Pro software. The concentration of intracellular
Ca2+ was calculated by averaging the ratio of fluorescent
signal acquired at 340 and 380 nm and expressed relative
to values of control wells.
Measurement of reactive oxygen species in live cells
ROS, the cellular marker of oxidative stress was detected
using the cell permeable fluorogenic probe CellROX
Deep Red (Invitrogen, Carlsbad, CA) that emits red
fluorescence upon oxidation in cells treated with glu-
tamate with and without B355252. Incubation of the
cells with B355252 and glutamate was performed as de-
scribed for previous assays. The amount of intracellular
ROS was determined by incubating cells with 5 μM
CellROX reagent for 30 min at 37°C. The media was re-
moved and the cells washed twice with DPBS. ROS level
was measured with the PheraStar (BMG Labtech.,
Durham, NC) at 640/655 nm, the excitation/emission
maxima for CellRox and expressed as a percentage of
control.
Immunoblot analysis
Sub-cellular fractions (cytosol and nuclear) were
extracted from treated and control cells by resuspension
of cells for 5 min in ice cold cell lysis buffer containing20 mM Tris pH7.4, 10 mM KCL, 3 mM MgCl2, 0.5%
NP40 and protease inhibitor cocktail (EMD Millipore,
Billerica, MA). The cells were lysed by repeated mixing
on ice with pipet. The lysates were transferred to
microcentrifuge tubes and centrifuged at 2,000 × g for
10 min. The resulting supernatant was stored as the
cytosolic fraction. The pellets were washed twice in cell
lysis buffer, resuspended in nuclear extraction buffer
(cell lysis buffer supplemented with 1% SDS), sonicated
briefly on ice and centrifuged at 20,800 × g for 30 min
at 4°C. The supernatants were saved in clean ice cold
tubes as nuclear fractions.
Protein concentrations were determined with the
Bradford reagent and 20 μG of protein per sample was
loaded on 10% NuPAGE BT gels (Invitrogen), subjected
to electrophoresis, and transferred to a PVDF membrane
(EMD Millipore). The blots were probed with monoclo-
nal antibodies to pERK1/2 and ERK3, and incubated
with enhanced chemiluminescent (ECL) goat anti-rabbit
IgG conjugated to horse radish peroxidase (HRP) as sec-
ondary antibody. The antigen/antibody complexes were
detected with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL) and exposed
to X-ray Films. To control for gel loading, membranes
were probed with anti GAPDH (cytosolic) or anti His-
tone H3 (nuclear) antibodies.Statistical analyses of data
The data are expressed as percent of mean values ±
standard deviation (SD) relative to the controls from at
least 3 independent experiments (n=6). Statistical ana-
lysis of results was performed in GraphPad PRISM
(GraphPad Software Inc). For experiments involving
more than two groups, statistical evaluation of the data
was performed using one-way ANOVA followed by
Bonferroni post test analysis. A value of p <0.05 was
considered to be statistically significant.
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